Outcomes* · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete resolution of endophthalmitis at 3 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
It is very uncertain whether combined steroid and antibiotic therapy changes complete resolution of endophthalmitis at 3 months' compared with antibiotics alone (very low certainty).
1 finding from 1 review
Visual acuity · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
Combined steroid and antibiotic therapy may leads to higher visual acuity 6/6 to 6/18 at 3 months' compared with antibiotics alone (low certainty).
2 findings from 1 review
Improvement in visual acuity at 3 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intraocular pressure ( · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
1 finding from 1 review
Adverse events at 3 to 12 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
Combined steroid and antibiotic therapy showed no clear difference in adverse events at 3 to 12 months' compared with antibiotics alone (low certainty).
1 finding from 1 review
Costs · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with endophthalmitis · people with bilateral age‐related cataracts (NRSs)
2 findings from 1 review
Complications · people with bilateral age‐related cataracts (NRSs)
It is very uncertain whether ISBCS changes complications compared with DSBCS (very low certainty).
2 findings from 1 review
Total costs per participant · people with bilateral age‐related cataracts (NRSs)
2 findings from 1 review
Total costs per QALY · people with bilateral age‐related cataracts (NRSs)
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
BCDVA · people with bilateral age‐related cataracts (NRSs)
The review found no eligible studies for this question.
2 findings from 1 review
Patient‐reported outcome measures (PROMs) · people with bilateral age‐related cataracts (NRSs)
The review found no eligible studies for this question.
2 findings from 1 review
Refraction NOT within 1.0 dioptres of target · people with bilateral age‐related cataracts (NRSs)
ISBCS showed no clear difference in refraction NOT within 1.0 dioptres of target compared with DSBCS (moderate certainty).
2 findings from 1 review
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every 4 weeks probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every 4 weeks showed no clear difference in adverse events at ≥ 12 months compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review